The Efficacy and Safety of Dose Escalation of Dorzolamide Used in Combination with Other Topical Antiglaucoma Agents

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 6, 2003, Pages 517-525

  Araie, Makoto ^a,g   Kitazawa, Yoshiaki ^b   Azuma, Ikuo ^c   Shirato, Shiroaki ^d   Hamanaka, Teruhiko ^e   Tomita, Goji ^a   Origasa, Hideki ^f  

^a UNIVERSITY OF TOKYO   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; NIFEDIPINE; NIPRADILOL; PILOCARPINE; TIMOLOL; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; SEBORRHEIC DERMATITIS; SORE THROAT; VISUAL DISORDER;

EID: 0346733031     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803322660431     Document Type: Article

References (22)

1. Lippa, E.A., Carlson, L.E., Ehinger, B., Eriksson, L.O., Finnstrom, K., Holmin, C., Nilsson, S.G., Nyman, K., Raitta, C., Ringvold, A., Tarkkanen, A., Vegge, T., Deasy, D., Holder, D., and Ytteborg, J. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 110:495-499, 1992.
2. Strahlman, E., Tipping, R., and Vogel, R. The International Dorzolamide Study Group. A double-masked, randomized one-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol. 113:1009-1016, 1995.
3. Strahlman, E., Tipping, R., and Vogel, R. The Dorzolamide Dose (Response Study Group. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Arch. Ophthalmol. 122:183-194, 1996.
4. Yamazaki, Y., Miyamoto, S., and Sawa, M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn. J. Ophthalmol. 38:92-96, 1994.
5. Kitazawa, Y., Azuma, I., Iwata, K., Tsukahara, S., Shiose, Y., Araie, M., Shirato, S., Mizogami, K., Mishima, H., Futa, R., and Komemushi, S. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose (response study in patients with glaucoma or ocular hypertension. J. Glaucoma 3:275-279, 1994.
6. The MK-507 Clinical Study Group. Long-term glaucoma treatment with MK-507, dorzolamide, a topical carbonic anhydrase inhibitor. J. Glaucoma 4:6-10, 1995.
7. Kitazawa, Y., Tsukahara, S., Iwata, K., Mizogami, K., and Mishima, H. Long-term treatment with MK-507 0.5% ophthalmic solution in primary glaucoma and ocular hypertension. Folia Ophthalmol. Jpn. 46:202-210, 1995.
8. Strahlman, E., Vogel, R., Tipping, R., and Clineschmit, C.M. The Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 103:1283-1293, 1996.
9. Keates, E.U., and Stone, R.A. Safety and effectiveness of concomitant administration of dipivefrin and timolol maleate. Am. J. Ophthalmol. 91:243-248, 1981.
10. Balfour, J.A., and Wilde, M.I. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 10:384-403, 1997.
11. Sugrue, M. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Retin. Eye Res. 19:87-112, 2000.
12. Ormrod, D., and McClellan, K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 17:477-496, 2000.
13. Le, H.H., Chang, M.R., Cheng, C.Q., Lee, D.A., and Hartenbaum, D. The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications. J. Ocul. Pharmacol. Ther. 15:305-312, 1999.
14. Takahashi, M., Nakajima, M., and Azuma, I. Interview concerning knowledge of glaucoma. Folia Ophthalmol. Jpn. 49:457-460, 1998.
15. Fingeret, M. Glaucoma medications, glaucoma therapy, and the evolving paradigm. J. Am. Optomet. Assoc. 69:115-121, 1998.
16. Friedenwald, J.S. Current studies acetazolamide (Diamox) and aqueous humor flow. Am. J. Ophthalmol. 40:139-147, 1955.
17. Shiose, Y., Kitazawa, Y., Tsukahara, S., Akamatsu, T., Mizokami, K., Futa, R., Katsushima, H., and Kosaki, H. Epidemiology of glaucoma in Japan-a nationwide glaucoma survey. Jpn. J. Ophthalmol. 35:133-155, 1991.
18. Tomita, G., Niwa, Y., Shinohara, H., Hayashi, N., Yamamoto, T., and Kitazawa, Y. Changes in optic nerve head blood flow and retrobular hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma. Int. Ophthalmol. 23:3-10, 1999.
19. Goto, W., Ota, T., Morikawa, N., Otori, Y., Hara, H., Kawazu, K., Miyawaki, N., and Tano, Y. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 958:10-19, 2002.
20. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 126:487-497, 1998.
21. Shirakashi, M., Iwata, K., Sawaguchi, S., Abe, H., and Nanba, K. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica 207:1-5, 1993.
22. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.